基于盒装设计的优化和评估基于脂质的纳米药物输送系统,用于甲的脑向
Asha Spandana K M1, Mohit Angolkar1, Mohamed Rahamathulla2
1Department of Pharmaceutics, JSS College of Pharmacy-Mysuru, JSS Academy of Higher Education and Research, Mysuru 570015, India.
Pharmaceuticals (Basel, Switzerland)
|June 27, 2024
概括
开发的布罗莫克里普丁载入的脂质纳米粒子 (BCR-SLN和BCR-NLC) 是为了改善帕金森病治疗的口服生物可用性. 这些纳米粒子增强了药物向大脑的输送,增加了治疗效果.
科学领域:
- 纳米技术 纳米技术
- 药品制造 药品制造 药品制造
- 神经科学是一个神经科学.
背景情况:
- 甲素 (BCR) 由于溶解性低和广泛的第一通代谢,表现出较差的口服生物利用性,限制了其在帕金森病 (PD) 中的使用.
- 脂质纳米颗粒提供了一种潜在的策略,可以提高BCR的生物可用性并克服其药理动力学限制.
研究的目的:
- 开发和描述含密素的固体脂质纳米颗粒 (BCR-SLN) 和纳米结构脂质载体 (BCR-NLC).
- 评估优化的BCR载脂纳米颗粒的体外和体内性能,以提高帕金森病的治疗效果.
主要方法:
- 利用盒子-贝恩肯设计 (BBD) 进行优化和高压均质化,用于纳米粒子制备.
- 具有粒子大小 (PS),多分散度指数 (PDI) 和捕获效率 (EE) 的纳米粒子特征.
- 评估了体外药物释放,细胞毒性,并进行了体内药理动力学和大脑分布研究.
主要成果:
- 优化的BCR-SLN:PS 219.21nm,PDI 0.22,EE 72.2%. 这是一个非常好的方法. 优化的BCR-NLC:PS 182.87nm,PDI 0.16,EE 83.57%. 这是一个非常好的方法.
- 两种配方均表现出双相 in vitro 药物释放 (即时随后持续).
- 药理动力学研究表明,与BCR溶液相比,BCR-SLN和BCR-NLC的血和大脑生物可用性得到改善.
结论:
- 含烯胺的脂质纳米颗粒 (BCR-SLN和BCR-NLC) 有效地提高了药物的生物可用性和进入大脑.
- 这些脂质纳米颗粒配方代表了一种有前途的方法,用于改善烯在帕金森病管理中的治疗疗效.
更多相关视频
相关概念视频
Drug Delivery: Overview
1.3K
The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
1.3K
Bioavailability Enhancement: Drug Permeability Enhancement
352
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
352
Modified-Release Drug Delivery Systems: Bioavailability
170
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
170
Modified-Release Drug Delivery Systems: Site-Targeted
164
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
164
Site-Targeted Drug Delivery Systems: Polymeric Carriers
160
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
160


